← back to search

Erik D. Roberson

University of California, Davis · US
Area of research
Physiology · Neurology
Research interest
Research interests include Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Amyotrophic Lateral Sclerosis Research, and Parkinson's Disease Mechanisms and Treatments.
h-index
78
citations
32,587
works
325
NIH funding
primary concept
Medicine
email

Recent publications

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
The Lancet Neurology 2025cited by 34position: middledoi
Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disorders
Molecular Neurodegeneration 2025cited by 16position: middledoi
Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia
Alzheimer s & Dementia 2025cited by 8position: middledoi
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
Nature Aging 2025cited by 8position: middledoi
Reduction of sphingomyelinase activity associated with progranulin deficiency and frontotemporal dementia
Neurobiology of Disease 2025cited by 4position: lastdoi
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology
Alzheimer s & Dementia 2025cited by 3position: middledoi
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
JAMA Neurology 2024cited by 27position: middledoi
Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals
Nature Communications 2024cited by 20position: middledoi
Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models
Cell Reports 2024cited by 19position: middledoi
Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration
JAMA Network Open 2024cited by 18position: middledoi
Multimerization of TREM2 is impaired by Alzheimer's disease–associated variants
Alzheimer s & Dementia 2024cited by 13position: middledoi
Quantifying Putative Retinal Gliosis in Preclinical Alzheimer's Disease
Investigative Ophthalmology & Visual Science 2024cited by 9position: middledoi
X‐chromosome-wide association study for Alzheimer’s disease
Molecular Psychiatry 2024cited by 6position: middledoi
Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia
Journal of Translational Medicine 2023cited by 49position: middledoi
Evaluation of the Electronic Clinical Dementia Rating for Dementia Screening
JAMA Network Open 2023cited by 31position: middledoi
Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations
Neurotherapeutics 2023cited by 25position: lastdoi
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease
European Journal of Nuclear Medicine and Molecular Imaging 2023cited by 23position: middledoi
Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals
Annals of Neurology 2023cited by 18position: middledoi
Temporal order of clinical and biomarker changes in familial frontotemporal dementia
Nature Medicine 2022cited by 131position: middledoi
Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders
Cell Reports Medicine 2022cited by 69position: middledoi
TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model
Science Translational Medicine 2022cited by 51position: middledoi
ASLPrep: a platform for processing of arterial spin labeled MRI and quantification of regional brain perfusion
Nature Methods 2022cited by 48position: middledoi
Periodontal Infection Aggravates C1q-Mediated Microglial Activation and Synapse Pruning in Alzheimer’s Mice
Frontiers in Immunology 2022cited by 42position: middledoi
Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients
Nature Aging 2022cited by 25position: middledoi
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Nature Medicine 2021cited by 362position: middledoi
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration
Neurology 2021cited by 103position: middledoi
Proposed research criteria for prodromal behavioural variant frontotemporal dementia
Brain 2021cited by 100position: middledoi
Aberrant regulation of a poison exon caused by a non-coding variant in a mouse model of Scn1a-associated epileptic encephalopathy
PLoS Genetics 2021cited by 34position: middledoi
Dysregulated clock gene expression and abnormal diurnal regulation of hippocampal inhibitory transmission and spatial memory in amyloid precursor protein transgenic mice
Neurobiology of Disease 2021cited by 32position: middledoi
Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization
Scientific Reports 2021cited by 31position: middledoi

Grants

UAB Alzheimer's Disease Research Center
NIH1P30AG086401-01$4,299,1822024–2029Contact PIRePORTER
Administrative Core
NIH5P30AG086401-02$792,0002024–2029Contact PIRePORTER
Administrative Core
NIH5P30AG086401-03$768,2382024–2029Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH1R01AG061785-01A1$760,8612021–2026Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH5R01AG061785-04$735,2492021–2026Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH5R01AG061785-03$732,6362021–2026Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH5R01AG061785-05$721,0762021–2027Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH5R01AG061785-02$720,7652021–2026Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH3R01AG061785-05S1$72,1072021–2027Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH3R01AG061785-04S1$67,5812021–2025Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH3R01AG061785-04S2$66,0992021–2026Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH3R01AG061785-03S1$50,6862021–2026Contact PIRePORTER
UAB Alzheimer's Disease Research Center
NIH1P20AG068024-01$1,109,4632020–2023Contact PIRePORTER
UAB Alzheimer's Disease Research Center
NIH5P20AG068024-03$1,098,0472020–2024Contact PIRePORTER
Administrative Core
NIH5P20AG068024-02$269,4922020–2023Contact PIRePORTER
Circadian changes in network excitability and Alzheimer disease pathogenesis
NIH1R56AG061785-01$702,7472019–2021Contact PIRePORTER
BIN1, Interneuron Activity, and Network Dysfunction in Alzheimer Disease
NIH1RF1AG059405-01$2,606,6742018–2023Contact PIRePORTER
UAB Training Program in Neurodegeneration
NIH5T32NS095775-09$217,6162017–2027Contact PIRePORTER
UAB Training Program in Neurodegeneration
NIH5T32NS095775-07$212,0552017–2027Contact PIRePORTER
UAB Training Program in Neurodegeneration
NIH2T32NS095775-06$210,7862017–2027Contact PIRePORTER
UAB Training Program in Neurodegeneration
NIH5T32NS095775-08$91,4722017–2027Contact PIRePORTER

Frequent collaborators

Andrew E. Arrant · University of Alabama at Birmingham9 papers (2014–2025)J. Nicholas Cochran · HudsonAlpha Institute for Biotechnology8 papers (2013–2021)Bruce L. Miller · University at Buffalo, State University of New York7 papers (2014–2025)Anthony J. Filiano · University of Alabama at Birmingham6 papers (2013–2018)Nicholas R. Boyle · Civitan International4 papers (2018–2025)David Geldmacher · University of Alabama at Birmingham4 papers (2012–2024)William W. Seeley · Hammersmith Hospital4 papers (2014–2025)Charles Murchison · City University of New York4 papers (2019–2024)Qin Wang · Northwest Minzu University4 papers (2015–2022)Lea T. Grinberg · Mayo Clinic in Arizona3 papers (2017–2025)Takashi Saito · UK Dementia Research Institute3 papers (2020–2024)Takaomi C. Saido · Keio University3 papers (2020–2024)Salvatore Spina · University Memory and Aging Center3 papers (2017–2025)Alicia M. Hall · University of Alabama at Birmingham3 papers (2013–2015)Jonathan R. Roth · University of Alabama at Birmingham3 papers (2019–2020)Brian A. Warmus · University of Alabama at Birmingham3 papers (2013–2016)Hunter B. Dean · University of Alabama at Birmingham3 papers (2019–2024)Yuhua Song · University of Alabama at Birmingham3 papers (2019–2024)Gil D. Rabinovici · Harvard University3 papers (2017–2020)Allen H. Young · University of Alabama at Birmingham3 papers (2013–2018)